All In Biotech

Free tool

FAERS Monitor: Silvadene

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017381 or its brand name (Silvadene, Silver Sulfadiazine). Reports on generic versions are filed under their own applications.

Reports

2,294

Serious

1,488

65% of reports

Hospitalization

779

Death reported

290

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use161
  • pain152
  • fatigue150
  • product use in unapproved indication146
  • nausea136
  • death121
  • diarrhoea118
  • drug ineffective115
  • chronic kidney disease109
  • dyspnoea108
  • rash99
  • anxiety95
  • fall95
  • pneumonia93
  • acute kidney injury90

Reports by year received

View as table
YearReports
200420
200517
200616
200726
200817
200942
201035
201134
201278
201349
201467
201598
2016200
2017151
2018181
2019185
2020194
2021204
2022176
2023160
2024119
2025112
2026112

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,865 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal10913.211.01,216
product use in unapproved indicationSignal1465.44.6525
acute kidney injurySignal905.44.4320
anxietySignal953.12.5132
pneumoniaSignal932.62.294
fallSignal952.62.195
painSignal1522.31.9110
rashSignal992.11.756
fatigue1501.81.551
dyspnoea1081.71.535
off label use1611.71.546
diarrhoea1181.71.433
nausea1361.61.329
death1211.31.18
drug ineffective1150.80.76

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.